In this study, we assessed a possible correlation of CD4 counts with the low-cost progression markers neopterin, 132-microglobulin (B2M), total lymphocyte count (TLC) and hemoglobin, and we investigated associations between progression :narkers and clinical parameters in HIV -1 seropositive Zambians. Of 147 HIV-1 seropositive patients presenting to an outpatient clinic in Lusaka, blood was taken for CD4 counts, serum progression markers and full blood count. A detailed clinical history and medical examination was taken at that point, and the patients were seen 3··monthly over the following 12 months. Further CD4 counts were taken after 6 and 12 months. Neopterin, B2M: lymphocyte count, and hemoglobin showed a strong correlation with CD4 count. Of the serum progression markers, neopterin was more sensitive than B2M to detect HIV related symptoms and to predict weight loss and death in the follow-up period. Lymphocyte count and hemoglobin were significantly lower in patients with oral candidiasis and those falling sick or dying in the follow-up period . Hemoglobin was also associated with past diarrhoea. When stratified by sex, the associations of hemoglobin were very strong in males, but weakel' in females . In conclusion, neopterin and B2M correlate well with C D~ counts in this African population. Neu~terin appears to be more sensitive for the clinical evaluat ion 0 :' the patients in this study. Hemoglobin might only be useful as a progression marker in male indi viduals .
Introduction
CD4 positive T lymphocytes are still a widely used and acknowledged progression marker in HIV infection. The gold standard for counting of T cell subsets is flow cytometry, which is expensive and requires advanced laboratory equipment. Alternative methods have been developed and introduced for settings with limited laboratory facilities and small health budgets. They include a simplified version of fluorescence activated cell sorting (FACScount), immunocytochemical labelling of blood smears, and methods based on CD4 antigen detection using ELISA related techniques (1 ,2). In this study, we measured absolute CD4 counts in HIV -1 infected persons using F ACScount analysers, and investigated their correlation with the serum progression markers neopterin and 132-microglobulin (B2M), and with hemoglobin and total lymphocyte count. We compared progression markers with clinical parameters and outcomes in these patients, and evaluated th eir us efulness in c;ecS \, :th l;mlled fi nancia l and labora tory fc c: l:ties in terms of e1m lcal value. cos t and feaslblllty o f the different tests .
Subjects and Methods
Between February and April 1995 blood was taken from 147 HIV-1 infected individuals at an out-patient clinic of the University Teaching Hospital in Lusaka, Zambia. All these patients took part in a randomised placebo-controlled trial to evaluate the efficacy of preventive treatment for tuberculosis, and attended the study clinic for review during the above mentioned period. Full details of the trial are given elsewhere (3) . At recruitment into this study, a detailed clinical history and examination was taken, and venous blood was drawn for a complete blood count and a F ACScount analysis of T cell subsets. Additional blood smears, prepared as for conventional hematological examination, and sera were stored at -20°C. Thereafter the patients were clinically evaluated 
Results
Of the 147 patients studied, 65 (44%) were female and the mean age was 31.8 years. Twenty-nine patients (20.1 %) had a history of herpes zoster infection. Diarrheal disease of more than 6 days during the previous 6 months was found in 45 patients (31 %). Eleven individuals (8%) presented with oral candidiasis, and 82 (56%) with lymphadenopathy. During the 12 months follow-up period 14 patients did not come back to the study clinic at any time, 4 patients were only followed up for 6 months and no clinical information is available for the time thereafter. The remaining 129 patients were followed up for 12 months: 85 (66%) stayed well or presented with minor clinical problems, and 44 patients (34%) fell ill with conditions such as diarrhoea or cough for more than 2 weeks, weight loss more than 10% of the body weight, illnesses requiring admission to hospital, or any opportunistic infections. Fourteen patients (11%) died. Table 2 shows the median values for progression markers at baseline. Thirty-one patients (25%) had a CD4 count higher than 400/f.11, 39 (32%) between 200 and 400/f.11, and 52 (43%) below 200/f.1L There was a significant difference between the median hemoglobin in females and males (11.5 vs 13 .6g/dL, p<O.OOl) but no difference between the sexes in any of the other laboratory parameters. Table 3 shows the rank correlation coefficients between the progression markers. All laboratory parameters were significantly correlated with CD4 counts. In Table 4 the median value of each progression marker for patients with and without particular clinical symptoms are shown: CD4 counts and neopterin were associated with most of the clinical parameters evaluated. Neopterin was more sensitive to predict weight-loss. CD4 percentages were less different than absolute CD4 counts in patients with candida and lymphadenopathy, but eGually predictive of events during the follow-up period. Also anemia and lymphopenia could predict death and sickness during follow-up, but not B2M (Table 4) . The median decline of CD4 counts over the 12 month follow-up period was -24/1l1 (-12.9%). The decline of CD4 counts was significantly higher in ' patients getting sick or dying during that period, and also in patients who presented with oral candidiasis at baseline (Table 4) .
Discussion
The F ACScount system was designed to provide automated absolute CD4 and CD8 T cell enumerations without the need for separate hematology instrumentation and highly skilled technicians. In our setup in Lusaka, routine hematology technicians were instructed to set up the instrument and run samples Table I ) is still high. In many African settings a full blood count will be the only routinely available measure of immune function. Anemia in HIV infection is of multifactorial origin. It has been shown that chronic immune stimulation with changes in the release of specific cytokines is associated with changes of iron metabolism and development of anemia, e.g. in patients with autoimmune disorders, malignant diseases, and chronic infections including HIV (6, 7) . In vitro studies demonstrated that antibodies in HIV positive sera could suppress the growth of bone marrow progenitors from HIV seropositive patients (8) . Other contributing factors for HIV associated anemia could be direct infection of erythroid progenitors, deficiency of micronutrients, and a blunted erythropoietin feedback mechanism (9). In our patients associations between hemoglobin and HIV progression were very strong in males but weaker in females, who frequently presented with anemia associated with pregnancy and child birth. Hemoglobin as a progression marker would probably also be of only limited value in commumtIes where parasitic infections and micronutrient deficiency is common. This was not the case in our study population from the urban and periurban areas of Lusaka. The serum progression markers neopterin and B2M have been shown to be nearly as good a predictor of survival as CD4 counts in HIV-l and HIV-2 infected West Africans (10). They are biochemical markers for Immune activation. Neopterin is released by monocytes/macrophages upon stimulation with s.terferon-g derived from activated T-lymphocytes : 1 In this study, neopterin was the most sensitive progression marker to predict weight loss. The strong power of neopterin to predict weight loss has been observed and discussed before (17) : in animal models interferon-y and tumor necrosis factor induce weight loss; the same cytokines synergistically activate macrophages to produce neopterin. The predictive value of B2M for HIV progression and mortality might differ between study populations. It has been strongly correlated with the risk of progression to AIDS in homosexual men (18) but not in intravenous drug users (19). In Gambian and Rwandan patients B2M predicted death (10,16). These patIents presented with considerabl y higher median B2M at baseline than our Zambian patI ents and could have been further advanced in their fIIV disease. It is also possible that the short follow-up period and the small number of deaths in our study was not powerful enough to detect an effect of B2M on death. Our observations suggest that neopterin is more sensitive than B2M for the clinical evaluation of HIV infected patients, at least during earlier stages of HIV disease. A further advantage of neopterin is the pos ~ibility to use urine instead of serum, which can increase cooperation in patients and communities w ho do not accept frequent blood testing. 
